Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal

Diabetes Care

Volumn 25, Issue 8, 2002, Pages 1271-1276

  Cozma, Lawrence S ^a   Luzio, Stephen D ^a   Dunseath, Gareth J ^a   Langendorg, Kirsten W ^b   Pieber, Thomas ^c   Owens, David R ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; REPAGLINIDE; ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; INSULIN; PIPERIDINE DERIVATIVE;

ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOOD INTAKE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TEST MEAL; AGED; BLOOD; COMPARATIVE STUDY; EATING; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; PANCREAS ISLET; SECRETION;

AGED; CARBAMATES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; EATING; FEMALE; GLIPIZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PIPERIDINES;

EID: 0036674465     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.8.1271     Document Type: Article

References (32)

1. Panzram G: Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:123-131, 1987
2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823-828, 1998
3. Yudkin JS, Blauth C, Drury P, Fuller J, Henley J, Lancaster T, Lankester J, Lean M, Pentecost B, Press V, Rothman D: Prevention and management of cardiovascular disease in patients with diabetes mellitus: an evidence base. Diabet Med 13 (Suppl. 4):S101-S121, 1996
4. Vehkavaara S, Seppala-Lindroos A, Westerbacka J, Groop PH, Yki-Jarvinen H: In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care 22:2055-2060, 1999
5. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring HU: Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101:1780-1784, 2000
6. Makimattila S, Virkamaki A, Groop PH, Cockcroft J, Utriainen T, Fagerudd J, Yki-Jarvinen H: Chronic hyperglycemic impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation 94:1276-1282, 1996
7. Akbari CM, Saouaf R, Barnhill DF, Newman PA, LoGerfo FW, Veves A: Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia. J Vasc Surg 28:687-694, 1998
8. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ: Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42:1050-1054, 1999
9. Avignon A, Radauceanu A, Monnier L: Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20:1822-1826, 1997
10. Bastyr EJ 3rd, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE: Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c: IOEZ Study Group. Diabetes Care 23:1236-1241, 2000
11. DeFronzo RA: Lilly lecture 1987: the triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667-687, 1988
12. Polonsky KS, Sturis J, Bell GI: Seminars in Medicine of the Beth Israel Hospital, Boston: non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334:777-783, 1996
13. Davies MJ, Rayman G, Grenfell A, Gray IP, Day JL, Hales CN: Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolerance. Diabet Med 11:432-436, 1994
14. DeFronzo RA: Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 35:389-397, 1992
15. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, Gerich J: Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22-29, 1992
16. Luzi L, DeFronzo RA: Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 257:E241-E246, 1989
17. Calles-Escandon J, Robbins DC: Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes 36:1167-1172, 1987
18. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, Tiengo A, Del Prato S: Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48:99-105, 1999
19. Holman RR, Steemson J, Turner RC: Postprandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia. Diabetes Res 18:149-153, 1991
20. Owens DR, Luzio SD, Ismail I, Bayer T: Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 23:518-523, 2000
21. Hanefeld M, Bouter KP, Dickinson S, Guitard C: Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 23:202-207, 2000
22. Owens DR: Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes. Eur J Clin Invest 29 (Suppl. 2):30-37, 1999
23. Wahlin-Boll E, Melander A, Sartor G, Schersten B: Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects. Eur J Clin Pharmacol 18:279-283, 1980
24. Jonsson A, Chan JC, Rydberg T, Vaaler S, Hallengren B, Cockram CS, Critchley JA, Melander A: Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes. Eur J Clin Pharmacol 56:711-714, 2000
25. ATP channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 293:444-452, 2000
26. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD: Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47:345-351, 1998
27. Kahn SE, Montgomery B, Ligueros-Saylan M: Nateglinide increases first phase insulin secretion and enhances glucose clearance in type 2 diabetes. Mexico City, Mexico, International Diabetes Federation Congress, 2000
28. Chiasson JL, Hamet P, Verdy M: The effect of Diamicron on the secretion and action of insulin. Diabetes Res Clin Pract 14 (Suppl. 2):S47-S51, 1991
29. Ligtenberg JJ, Venker CE, Sluiter WJ, Reitsma WD, Van Haeften TW: Effect of glibenclamide on insulin release at moderate and high blood glucose levels in normal man. Eur J Clin Invest 27:685-689, 1997
30. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE: Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24:983-988, 2001
31. de Souza CJ, Russo P, Lozito R, Dunning BE: Differential effects of short and long duration insulinotropic agents on meal-related glucose excursions. Diabetes Obes Metab 3:73-83, 2001
32. Yki-Jarvinen H: Toxicity of hyperglycaemia in type 2 diabetes. Diabete Metab Rev 14 (Suppl. 1):S45-S50, 1998